Designing a Small Molecule for PET Radiotracing: [18F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies
Molecules · 2025
DOI: 10.3390/molecules30183696 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2025. Verfasst von Francesco Mastropasqua und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Central Nervous System Diseases, Fluorine Radioisotopes, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: #NEXTGENERATIONEU (NGEU), Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP).
Abstract (Originalsprache)
P-Glycoprotein (P-gp, also known as MDR1 or ABCB1) is an ATP-binding cassette (ABC) transporter that actively effluxes a wide range of structurally and functionally diverse molecules, playing a crucial role in drug absorption, distribution, and excretion. P-gp is highly expressed at key biological barriers, such as the blood–brain barrier (BBB), intestine, liver, and kidneys, and it serves as a gatekeeper against xenobiotics and therapeutics. Its dysregulation is involved in multidrug resistance (MDR), epilepsy, cancer, infectious diseases, and neurodegenerative disorders. Several small molecules were synthesized using SAfIR and SAR, and, among them, [18F]MC225 showed the most promising results for in vivo human studies, with appropriate pharmacodynamics and pharmacokinetics profiles for in vivo use. [18F]MC225 is currently being employed in PHASE II human trials at the UMC Groningen, the Netherlands, in patients diagnosed with AD, PD and MCI, as well as PHASE II human trials at the Policlinico Gemelli in Rome Italy to diagnose P-gp resistant depression. Preliminary studies show that [18F]MC225 radiotracer is behaving according to the initial predictions, that is, it accurately diagnoses the aforementioned pathologies, more so than previously developed small molecules for the same goal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy.
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen (UMCG), University of Groningen, 9712 CP Groningen, The Netherlands.
- Biofordrug, Spin-Off of the University of Bari, Via Dante 95/99, 70019 Bari, Italy.
ORCID-Profile: Francesco Mastropasqua, Gert Luurtsema, Cristina Filosa, Nicola Antonio Colabufo
Förderung
- #NEXTGENERATIONEU (NGEU)
- Ministry of University and Research (MUR)
- National Recovery and Resilience Plan (NRRP)
- MNESYS
- National Research Council (CNR-Italy)
Zitieren
APA
Mastropasqua, F., Luurtsema, G., Filosa, C., & Colabufo, N. A. (2025). Designing a Small Molecule for PET Radiotracing: [18F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies. Molecules. https://doi.org/10.3390/molecules30183696
Vancouver
Mastropasqua F, Luurtsema G, Filosa C, Colabufo NA. Designing a Small Molecule for PET Radiotracing: [18F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies. Molecules. 2025. doi:10.3390/molecules30183696
BibTeX
@article{Mastropasqua2025,
author = {Mastropasqua, Francesco and Luurtsema, Gert and Filosa, Cristina and Colabufo, Nicola Antonio},
title = {Designing a Small Molecule for PET Radiotracing: [18F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30183696}
}
EUVIMED